Generalized Myasthenia Gravis (gMG)
DNTHDianthus TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Claseprubart (DNTH103) in Generalized Myasthenia Gravis (gMG). The expected timing is based on the latest available company guidance and may change.
MaGic trial. 9/8/25- Positive topline data from Ph2 trial reported. End-of-Ph2 FDA meeting planned. 10/29/25– Presented trial data at AANEM’25; Ph3 trial in 2026. 03/09/26:- Ph3 gMG trial initiation expected Mid-2026. Top-line results expected in H2 2028. EoPh2 FDA meeting completed in Q1 2026. MaGic Ph2 data presented at MDA 2026. 05/05/26:- FDA Orphan Drug Designation in MG; EMERGE Ph3 mid-2026 start, 2H 2028 topline; MaGic data at AAN. 06/29/26:- EMERGE Ph3 trial initiated. Topline results expected in H2 2028. 08/04/26:- EMERGE Ph3 dosing detailed; topline remains expected in H2 2028.
Verification
Confirm timing and program details against the company announcement or filing.